Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.
Ehsani M, Bartsch S, Rasa SMM, Dittmann J, Pungsrinont T, Neubert L, Huettner SS, Kotolloshi R, Schindler K, Ahmad A, Mosig AS, Adam L, Ori A, Neri F, Berndt A, Grimm MO, Baniahmad A. Ehsani M, et al. Among authors: grimm mo. Oncogene. 2022 Jun;41(23):3263-3277. doi: 10.1038/s41388-022-02333-7. Epub 2022 May 5. Oncogene. 2022. PMID: 35513564 Free PMC article.
Antithetic hTERT Regulation by Androgens in Prostate Cancer Cells: hTERT Inhibition Is Mediated by the ING1 and ING2 Tumor Suppressors.
Bartsch S, Mirzakhani K, Neubert L, Stenzel A, Ehsani M, Esmaeili M, Pungsrinont T, Kacal M, Rasa SMM, Kallenbach J, Damodaran D, Ribaudo F, Grimm MO, Neri F, Baniahmad A. Bartsch S, et al. Among authors: grimm mo. Cancers (Basel). 2021 Aug 10;13(16):4025. doi: 10.3390/cancers13164025. Cancers (Basel). 2021. PMID: 34439179 Free PMC article.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK. Fizazi K, et al. Among authors: grimm mo. J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761. J Immunother Cancer. 2022. PMID: 35977756 Free PMC article. Clinical Trial.
292 results